Menu di pagina
- IRE Research and Technology
- IRE Competitive Grants
- PerfeTTO
- INNOVA
- Immune Metabolism Dysregulation and Efficacy of Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer (NSCLC)
- Artificial Intelligence and Machine Learning Based Risk Prediction Model for Improving Endometrial Cancer Clinical Management
- Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation after robot-assisted surgical treatment of genitourinary cancers
- Deciphering KEAPness for Improved Immunotherapy Prediction and Treatment
- MiRNA-based therapeutic approach to fight triple negative breast cancer
- Beyond the creation of a living biobank: dissecting the transcriptomic landscape of Gastro-entero-pancreatic neuroendocrine neoplasms
- Multidimensional assessment of virus-associated head and neck cancer patients for the discovery of predictive biomarkers to guide clinical intervention
- TArgeting drug resistant melanoma with miCroRNAs delivered by Lipid NanoparTICles (TACTIC)
- Addressing liver fibrosis prevention and treatment: an unbiased query on the hepatic microenvironment with a perspective targeting of the pro-fibrotic kinase HIPK2
- Analyses of HPV and host body fluid biomarkers as non-invasive strategy for detection of head and neck cancer relapse
- Deciphering Biology of R/R DLBCL Subtypes: miRNA Biomarkers for Optimizing Treatment and Survival
- Clinically approved drugs targeting pyruvate kinase M2: a drug repurposing pathway to move forward the treatment of glioblastoma
- Developing a Biobank Network Among Major Sarcoma Treatment Centers to Improve Biomedical Research
- Identification and Validation of Prognostic and Predictive Biomarkers, Including E3 Ubiquitin Ligases and MicroRNA Signature, for the Development of New Immunotherapeutic Approaches in Glioma
- Heal Italia
- D3 4 Health
- TRIglIFO2 project
- Poc MIMIT Project
- The PROMlSE project
- The 4Immunogenomics project
- Project ERBB2
- Project NANO-COVID-TEST
- Progetto DOMINO – Lazio Innova
- Project GEMMA – Lazio Innova
- Project COMETA
- Exploring the role of Bcl-2 family in the immune surveillance of melanoma: from mechanisms to therapeutic perspectives
- Exploring how endothelin-1/PIEZO axis intersects mechanical forces to fuel PARP inhibitor resistance in ovarian cancer
- The PROGRESS Project
- ULYSSES Project
- VerSiLiB Project
- PRODIGI Project
- LASERBLOOD Project
- BioCIPN Project
PRODIGI Project

Full title: “A PLATFORM OF ORGANOTYPIC MODELS DERIVED FROM PATIENTS TO HIGHLIGHT THE EFFICACY OF POLIFENOLIC COMPOUNDS TO USE IN COMBINATION IN IMMUNOTHERAPY IN LUNG CANCER (PRODIGI)”
Web site of the Foundation Rome-Technopole: https://www.rometechnopole.it/
Project description
The PRODIGI project, of which IFO-Istituto Nazionale Tumori Regina Elena (IRE) of Rome is the Coordinator, is realized in partnership with Università degli Studi “Magna Graecia” di Catanzaro - Dipartimento di Scienza della Salute and the SME company Med - Systems S.R.L.
The project aims to standardise and spatially transcribe a tumoroid platform to assess the efficacy of novel microencapsulated nutraceuticals in combination with immunotherapy in lung cancer patients.
Non-small cell lung cancer (NSCLC) is the highest rate of morbidity and mortality due to cancer in the world (https://www.who.int/news-room/fact-sheets/detail/lung cancer).
The proposed tumor platform represents a significant innovation since, while preserving tissue organization, it allows to assess with high predictability and robustness, the preclinical efficacy of single or combined therapies. Another advantage of this platform is its ability to preserve the specific characteristics of the original tissue, maintaining the uniqueness and heterogeneity of individual patients, while ensuring compliance with the principles of precision medicine.
These unique features of the proposed platform allow existing technologies, such as 2D or 3D patient-derived cell line cultures, to overcome limitations in losing their original spatial configuration, Fundamental for the dynamic interactions between the various cellular and non-cellular components present in the tumour environment. On the other hand, the use of in vivo models fails to fully replicate complex interactions between tumor tissue and the immune system, because of the considerable differences between species. The importance of standardizing new non-animal approaches is supported by recent efforts in the scientific community to fund projects that go beyond animal models. The spatial transcriptomic analysis that PRODIGI implements represents a significant step forward and will contribute to the expansion of knowledge and the promotion of the digital transition. This approach will allow subclasses of TIME to be defined and new signal paths to be identified which can be operated to improve the effectiveness of immunotherapy. Finally, the innovative combination of nutraceuticals with immunotherapy represents a promising opportunity even with low environmental impact.
Project start date: 10/06/2024
Project end date: 31/12/2025
Purpose
The PRODIGI project is aimed at carrying out research and development activities for: 1) the characterisation of nutraceuticals, with reduced environmental impact, more bioavailable and effective, also in resistance to traditional cancer therapy, Innovative micro-encapsulation technology; 2) Standardisation of a platform of organotype models derived from patients to assess the efficacy of new compounds in combination with immunotherapy in lung cancer; 3) implementation of advanced models and products of TRACEABILITY along the whole chain that leads to the use of natural products for human health
The project is divided into three Work Packages (WP) and will be coordinated by the respective three leaders through periodic meetings of update and critical analysis.
WP1. Formulation and pharmacotoxicological characterization of polyphenolic nutraceuticals microencapsulated.
WP2. Standardization of a platform of pre-clinical models derived from NSCLC patients for the evaluation of the efficacy of novel nutraceutical drugs used in monotherapy or in combination with immunotherapeutic (ICI) or chemo-immunotherapy.
WP3. Implementation and development of advanced traceability models and products along the supply chain nutraceutical products.
IFO-IRE as Coordinator, is the leader and participates with its research activities within the WP2.
Contacts
Principal Investigator: Dr. Paola Nisticò, paola.nistico@ifo.it
Results
PRODIGI has achieved significant advances in the development of nutraceutical-based strategies to potentiate lung cancer immunotherapy. Novel microencapsulated formulations of bergamot polyphenols and Cynara extracts demonstrated selective antitumor activity in non-small cell lung cancer (NSCLC), reducing tumor cell viability and inducing apoptosis through modulation of redox homeostasis, in vitro. Advanced organ-on-chip technology, reproducing the gut-liver-lung axis, enabled pharmacological characterization and demonstrated the stability and delivery of bioactive polyphenols to lung cells.
A major breakthrough was the establishment of a patient-derived organotypic tissue slice platform preserving the complexity and spatial organization of the tumor immune microenvironment. Notably, treatment with microencapsulated bergamot polyphenols enhanced T- and B-cell infiltration and their spatial organization into immune aggregates suggestive of tertiary lymphoid structures, highlighting their potential to promote coordinated antitumor immune responses. Spatial transcriptomics workflows were also established to enable high-resolution investigation of tumor-immune interactions.
The project also delivered an advanced digital traceability platform, integrating heterogeneous datasets, real-time process monitoring, predictive analytics, and quality control across the entire nutraceutical supply chain, ensuring transparency, reproducibility, and product reliability.
Together, these achievements provide a strong translational foundation for combining nutraceuticals with immune checkpoint inhibitors to improve lung cancer treatment.
Financial Support
PNRR, financed by Sapienza Università di Roma.
Proposal number SAP01-2023-000077 approved with PEC n° prot. 2024- URM1SAM-0107510 of 10/06/2024.
The total grant of the project is 675.240 euro (CUP B83C22002820006)
The GRANT assigned to IFO-IRE is 240.000,00 euro
The funding resources are from the public call “BANDO A CASCATA PROGETTO ECS ROME TECHNOPOLE CODICE PROGETTO ECS 0000024 - CUP B83C22002820006 - SPOKE 1 E 6” Determination of Sapienza Università di Roma Rep. n° 2490 n. Prot. 94493 of 29/09/23, under the “Piano Nazionale di Ripresa e Resilienza, Missione 4, ‘Istruzione e Ricerca’ - Componente 2 ‘Dalla ricerca all’impresa’ - Investimento 1.5, finanziato dall’Unione europea – NextGenerationEU”.




